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EDITORIAL COMMENT
Restoring Sinus
Rhythm in Atrial Fibrillation
A Pyrrhic Victory?*
Paul Dorian, MD, Iqwal Mangat, MD
Toronto, Ontario, Canada
“The future ain’t what it used to be.”
—Yogi Berra
Atrial fibrillation (AF), at the very least, is a fruitful subject
for both the clinician and basic scientist. Since 1965,
PubMed has listed 6,329 publications with “atrial fib-
rillation” in the title, with 1,235 such articles between
January 2001 and December 2002. In light of the Atrial
Fibrillation Follow-up Investigation of Rhythm Manage-
ment (AFFIRM) parent study (1), which showed that in
patients with AF and a risk of stroke, the strategy of
restoring and maintaining sinus rhythm was not superior to
the strategy of rate control, one must ask whether the
relative efficacy of different drugs used to restore and
maintain sinus rhythm is a topic worth discussion.
See page 20
Despite the parent AFFIRM study, most clinicians
would answer “yes,” because the treatment of AF remains
important, and many patients are sufficiently symptomatic
that a strategy of rate control is inadequate. The clinician
treating a patient with highly symptomatic AF is thus faced
with the difficult choice between the rhythm control strat-
egy, which is associated with a nontrivial risk of serious,
potentially fatal adverse events as well as the burden of drug
toxicity and the likelihood of drug inefficacy, and the rate
control strategy, which may have limitations for symptom
control in the individual patient. It is important to recall
that patients were eligible for the AFFIRM parent study
only if the investigator and patient were prepared to
undertake either rhythm or rate control strategies, thus
suggesting, importantly, that patients with severe symptoms
during AF may not have been included in the study.
With that background, the AFFIRM First Antiarrhyth-
mic Drug Substudy investigators (2), in this issue of the
Journal, have added important information to the available
data on the effectiveness of antiarrhythmic drug therapy in
patients with AF. In particular, the AFFIRM investigators
have chosen a potentially more clinically relevant end point
of antiarrhythmic drug efficacy, as compared with the more
“conventional” end points, such as the “time to first recur-
rence of AF.” In the current study, “efficacy” is defined as
the presence of sinus rhythm at follow-up visits, without the
requirement for intervening electrical or pharmacological
cardioversion, and the absence of highly symptomatic AF
episodes, which would lead to the discontinuation of the
initially assigned antiarrhythmic drug. Although the defini-
tion of “drug failure” in this study is not unambiguous
(recurrent AF with spontaneous reversion to sinus rhythm
did not necessarily constitute a drug failure), this study,
appropriately, does not consider asymptomatic or minimally
symptomatic recurrences as a “failure” or as necessitating
drug discontinuation or change. Such an approach is much
more similar to routine clinical care than previous antiar-
rhythmic drug trials in AF, where the end points almost
always included any symptomatic occurrence of AF, as well
as some asymptomatic occurrences.
The conclusions with respect to drug efficacy and adverse
effects are nevertheless quite consistent with previous studies
of various antiarrhythmic therapies in AF. For example, in
the Canadian Trial of Atrial Fibrillation (3), the one-year
rate of freedom from recurrent AF was 69% in the amio-
darone group and 39% in patients treated with either sotalol
or propafenone, remarkably similar to the composite end
points of drug success in the current study (amiodarone vs.
class I: 62% vs. 23%; amiodarone vs. sotalol: 60% vs. 38%;
sotalol vs. class I: 34% vs. 23%). The inventive analysis of
the First Antiarrhythmic Drug Substudy investigators,
comparing drugs or classes of drugs to each other in a
pairwise fashion, thereby allowing individual patients to be
“counted more than once,” makes it somewhat difficult to
interpret the overall probability of effectiveness of any given
drug, but the overall results quite convincingly show that
amiodarone is superior to either sotalol or class I drugs, even
in patients carefully selected to have the lowest possible risk
of adverse effects from any of these therapies. Furthermore,
the investigators show that by one year, at most two-thirds
of patients on amiodarone are in sinus rhythm and receiving
effective drug therapy, and by five years, far fewer than
one-half of patients on any drug therapy, including amio-
darone, are still receiving effective therapy. Given that AF
rarely remits spontaneously and, in fact, tends to progress,
the current report suggests that rhythm control using
antiarrhythmic drugs is frequently not a useful or effective
long-term strategy.
Despite a relatively low incidence of adverse effects severe
enough to cause drug discontinuation at one year (13% on
amiodarone and 16% on sotalol), in the very long run, no
drug therapy was both superbly effective at maintaining
sinus rhythm and associated with good patient tolerance.
Additionally, the substudy results suggest that therapy with
class I antiarrhythmic agents is frequently associated with
adverse effects requiring drug discontinuation (39% at 1
year) and inefficacy (only 35% of patients meeting the
composite end point of success by four months in any of the
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comparisons). Thus, although the comparison of efficacy
between sotalol and class I agents is limited because of early
termination of this arm of the study due to futility, one may
still reasonably conclude that the use of class I agents, even
in patients selected to have a low risk of adverse events, is
not a rewarding strategy in patients meeting the AFFIRM
entry criteria. Furthermore, there is a substantially higher
mortality rate in patients initially assigned to class I drug
therapy than in those initially assigned to amiodarone or
sotalol, even though most of the deaths occurred well after
the class I drugs were stopped and the majority of deaths
occurred after the first year. Additionally, most of these
deaths were not “arrhythmic,” which at first glance raises the
worrisome hypothesis that class I drugs, even taken for a
relatively brief period, cause long-term consequences that
may lead to death after the drug is discontinued. However,
it is important to note that of the 69 deaths that occurred
over the duration of the study, 24 patients were taking
amiodarone at the time of death, 10 patients were taking
class I drugs, 8 patients were taking sotalol, and 27 patients
were not taking antiarrhythmic drugs.
What does all this mean for the practicing clinician?
Medicine is still an art. Subjective, patient-perceived quality
of life, as well as the patient’s own perceptions of the risk of
antiarrhythmic therapy compared with its potential benefits,
needs to be individually assessed in each and every patient
with AF. Although the AFFIRM parent study has reported,
in abstract form, equivalent quality-of-life outcomes in the
rate-control arm versus rhythm-control arm, there were
clearly many patients with AF who have unexpectedly severe
symptoms that can only be substantially improved if sinus
rhythm is restored. Additionally, as mentioned previously,
physicians were likely to have an enrollment bias toward
recruiting patients who were mildly or minimally symptom-
atic, making the results of this study less generalizable to the
patient with disabling symptoms during AF. As was done in
the setting of this substudy, clinicians need to carefully
establish, before antiarrhythmic therapy is contemplated,
explicit criteria of drug efficacy (for the particular patient)
and persist with therapy only if these criteria are fulfilled.
There are options in the restoration and maintenance of
sinus rhythm that were not a part of the AFFIRM drug
substudy. For example, there is intriguing and plausible
evidence that impeding the actions of angiotensin II on the
heart may reduce the burden of AF. In a randomized,
blinded study, the combination of amiodarone plus irbesar-
tan led to a lower rate of AF recurrence than amiodarone
plus placebo (4). In the Trandolapril Cardiac Evaluation
(TRACE) study, treatment with trandolapril led to a lower
incidence of new-onset AF (defined as an outpatient elec-
trocardiogram documenting the presence of AF) in patients
with reduced left ventricular function after myocardial
infarction, compared with placebo (5). Furthermore, beta-
blocker therapy may have independent “antiarrhythmic”
effects in AF. Metoprolol led to a lower risk of AF
recurrence after cardioversion, as compared with placebo, in
a randomized, controlled study (6), and beta-blockers plus
amiodarone may have synergistic effects on arrhythmia
prevention, at least for ventricular arrhythmias (7). Addi-
tionally, it cannot be overemphasized that blood pressure
control is extremely important in patients with AF, and it is
possible that some of the beneficial effect of beta-blockers or
medications that affect the renin-angiotensin system may be
related to their effect on blood pressure.
It is important to remember that neither the AFFIRM
study nor the current drug substudy attempted to discern
the difference in outcome between those AF patients who
achieve and maintain sinus rhythm and those who do not.
These studies are merely assessing some of the currently
available clinical strategies that are used for the treatment of
AF, and they have clearly answered some very important,
clinically relevant questions. However, given the large num-
ber of patients with refractory, exceedingly symptomatic
AF, there is still a role for the development and utilization
of new methods that may be more effective in the long-term
maintenance of sinus rhythm, including novel atrial selective
antiarrhythmic drugs and various nonpharmacologic ap-
proaches.
Despite substantial progress in the understanding of the
electrophysiologic mechanisms of AF (8), as well as a
plethora of pharmacologic, electrical pacing-based, and
ablative strategies to manage AF, its management continues
to be a very considerable challenge. For most patients with
AF, the heart is not only a pump but also a metaphor.
Therefore, cardiac symptoms occupy a larger section of our
patients’ consciousness than objective abnormalities in car-
diac function would warrant, and the dilemma of rate versus
rhythm will continue to be with us.
Based on this substudy data, the parent AFFIRM study,
as well as other recent, large trials in AF—Pharmacological
Intervention in Atrial Fibrillation (PIAF) (9) and Rate
Control versus Electrical Cardioversion (RACE) (10)—it is
very clear that all patients with AF not due to a reversible
cause and with risk factors for stroke should be permanently
anticoagulated with warfarin. It seems reasonable for all of
them to be treated with a drug that will reduce the rapid
ventricular rates expected with AF (among those with
normal atrioventricular node function), in the case of
recurrence of AF or as a primary strategy. Beyond that, a
thorough discussion with the patient of the anticipated
benefits and risks of sinus rhythm maintenance using
cardioversion, as necessary, and antiarrhythmic drug therapy
is warranted. If drug efficacy is the primary and most
important goal, then amiodarone is clearly the most effective
agent available. However, a strategy of beginning with an
alternative drug and changing to amiodarone only if the
initial therapy is ineffective is also quite reasonable. This is
particularly true for sotalol, because class I agents as initial
therapy are fraught with a relatively high risk of adverse
effects, early inefficacy, and a hypothetical but potentially
worrisome future risk of death. The AFFIRM First Anti-
arrhythmic Drug Substudy investigators have done the
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cardiology community a considerable service with their
careful and comprehensive investigation.
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